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Chapter 1 
 
Introduction 
 
1.1 – DNA damage response and repair 
Prevention of modifications to our genetic code from spontaneous and 
environmental modifiers is a constant battle facing all cells. Current estimations suggest 
that each cell could face up to 105 lesions per day from spontaneous errors. The 
spontaneous errors are the result of mismatching of bases during DNA replication, 
interconversion of bases by deamination, and modification by alkylation. Additionally, 
reactive oxygen species (ROS) derived from normal cellular metabolic processes can 
oxidize DNA bases and create breaks in the DNA backbone. Environmental 
modifications to the DNA are produced by chemical and physical sources. Examples of 
these include ultraviolet radiation (UV) and ionization radiation (IR). Ultraviolet 
radiation from sunlight exposure can induce pyrimidine dimers and 6-4 photoproducts 
resulting in 105 lesions per cell per day
1,2.  Exposure to ionization radiation from cosmic 
radiation, chemical agents used in cancer chemotherapeutics, and medical treatments 
using X-ray or radiotherapy can cause DNA bases to be oxidized resulting in the 
formation of single-strand and double-strand DNA breaks (SSBs and DSBs), as well as 
interstrand cross-links.  
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ATR and CHK1 Activation  
 
The major regulators of the DNA-damage response (DDR) are the 
phosphoinositide 3-kinase (P3IK)-related protein kinases (PIKK’s), including the ataxia-
telangiectasia mutated (ATM) and RAD3 related kinase (ATR).  ATR is a large kinase 
with a strong preference for phosphorylating serine or threonine residues that follow a 
glutamine residue. ATR activation occurs every S phase to regulate the firing of 
replication origins, the repair of damaged replication forks, and to prevent premature 
mitosis.3 
Although ATR is activated in response to many different types of DNA damage, 
there is evidence that a single structure may be responsible for this activation. When a 
cell undergoes replication stress, stalling or collapsing of the fork, there is an uncoupling 
of the DNA helicase from the DNA polymerase. This uncoupling result in long stretches 
of single stranded DNA (ssDNA) that becomes coated with replication protein A (RPA). 
The RPA coated ssDNA serves as the initial recognition factor for ATR signaling.4-6  
During DNA repair and replication, stretches of single-strand DNA (ssDNA) are 
formed as the DNA is unwound. Left unprotected, this ssDNA is susceptible to 
modifications that could lead to mutations in the genome. Replication protein A is the 
eukaryotic ssDNA binding protein and by binding to the ssDNA, protects it from 
modification during repair.7,8 The RPA-ssDNA complex is required for localization of 
ATR to sites of damage. The localization occurs through a direct interaction of the RPA-
ssDNA complex with ATR-interacting protein (ATRIP). Although ATRIP is a separate 
protein from ATR, it can be considered an obligate subunit of ATR as the stabilities of 
ATR and ATRIP are linked, their association is unregulated, and there is no known 
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difference in phenotypes from the loss of ATRIP or ATR.3,6 The binding of ATRIP to 
RPA involves an acidic alpha helix in ATRIP that binds to a basic cleft in the N-terminal 
domain of the RPA70 subunit (RPA70N).9  
Although localization of the ATR-ATRIP complex can be attributed to the 
interaction with the RPA-ssDNA complex, the activation of ATR cannot. Activation of 
ATR requires the co-localization of the ATR-ATRIP complex with the RAD9-RAD1-
HUS1 (9-1-1) complex. The 9-1-1 complex is a heterotrimeric ring-shaped molecule that 
is homologous in sequence to the replicative sliding clamp proliferating cell nuclear 
antigen (PCNA). The 9-1-1 complex is loaded onto a stretch of DNA adjacent to the 
RPA-ssDNA complex, in an ATR-dependent reaction involving the clamp loader 
RAD17.10 RPA is also crucial for the loading of the 9-1-1 complex, as it imparts 
specificity to the loading of the 9-1-1 complex to the 5’ primer end. This 5’-junction 
substrate containing the RPA-ssDNA complex, is the structure that normally results in 
the activation of ATR as it is the resulting DNA structure when a polymerase stalls and is 
uncoupled during DNA replication.11 The Rad 9 protein possesses a 120 amino acid c-
terminal “tail” containing at least ten serine and threonine phosphorylation sites, in which 
one of these sites is phosphorylated by ATR but is not required for CHK1 activation. The 
other sites are phosphorylated by unknown kinases and at least one other site is essential 
for the activation of CHK1.12,13 
In Saccharomyces cerevisiae it is reported that the 9-1-1 complex is responsible 
for directly activating ATR but there is no evidence that this occurs in other organisms. In 
humans there are two mediator proteins, Topoisomerase Binding Protein 1 (TopBP1) and 
Claspin, which are responsible for the activation of the CHK1.13 The 9-1-1 complex 
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recruits through RAD9 the topoisomerase-binding protein-1 (TOPBP1). TOPBP1 
contains multiple BRCA1 C-terminal (BRCT) domains and is required for ATR 
activation in vivo. Recruitment of TOPBP1 requires that the C-terminal tail of RAD9 be 
phosphorylated at serine 387. Phosphorylation of Ser387, creates a recognition site for 
the BRCT I and II domains of TOPBP1, which recruits TOPBP1 to ATR. TOPBP1 also 
contains an ATR activation domain, located between BRCT domains VI and VII, which 
interacts and activates the ATR-ATRIP complex in vitro. The mechanism by which 
TOPBP1 activates the ATR-ATRIP complex remains poorly understood as the primary 
binding site for the activation domain of TOPBP1 is located on ATRIP and mutation to 
this region block activation.14,15 Claspin is thought to already be present at active 
replication forks during replication and is phosphorylated in an ATR dependent manner. 
Once Claspin is modified it binds to CHK1, recruiting CHK1 to sites of RPA-coated 
ssDNA. This brings CHK1 in close proximity to active ATR, where it can then be 
phosphorylated by CHK1 rendering it active.16,17 Recent studies have found that TopBP1 
and Claspin are enough to activate CHK1 in the absence of RPA-coated ssDNA in 
vitro.18 
 Additional mediator proteins have been found to be involved in the activation of 
CHK1 in response to replication stress, including Timeless, Tipin (Timeless-interacting 
protein) and RHINO (Rad9-Rad1-Hus1 interacting nuclear orphan). Timeless is known to 
bind both ATR and CHK1 whereas Tipin is known to interact with RPA32 and is 
required for stable interactions of Claspin with stretches of RPA-coated ssDNA. RHINO 
was recently identified based on its interactions with 9-1-1 complex. The interaction 
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maps to the N-terminal portion of RHINO, and depletion of RHINO was shown to lead to 
a reduction of CHK1 phosphorylation. 19-21  
 
 
 
Figure 1. Major players in the CHK1 phosphorylation signaling cascade. 
 
DNA Repair Pathways 
To defend our genome against the hundreds of thousands of DNA lesions, our 
cells have developed multiple repair pathways; each specialized in repairing a different 
type of damage. Errors in replication that result in the mismatching of bases or 
insertion/deletion of bases are corrected by mismatch repair (MMR). Sites of dinucleotide 
repeats are unstable in some human cancers and display a “microsatellite instability” that 
is the result of defects in MMR. These defects are commonly seen in hereditary 
nonpolyposis colorectal cancer (HMPCC). The process of MMR can be broken down 
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into four steps: (1) recognition of the mismatch (2) recruitment of additional MMR 
factors (3) exonucelase degradation past the mismatch (4) re-synthesis of the excised 
tract.  
Ultraviolet radiation resulting in the formation of 6-4 photoproducts and 
pyrimidine dimers, as well as bulky lesions like the polycyclic aromatic hydrocarbon 
benzo[a]pyrene are repaired by nucleotide excision repair (NER). Distortions in duplex 
DNA are recognized by XPC. The duplex DNA is unwound by two helicases, XPD and 
XPF, in TFIIH and signals for the formation of the pre-incision complex. Two 
endonucleases, XPF and XPG, cut the duplex and a 24-32 bp fragment containing the 
lesion is excised from the DNA. The resulting gap is filled by gap-filling replication 
machinery.  
Ionizing radiation from X-rays, alkylating agents, and reactive oxygen species 
that induce the formation of abasic sites, 8-oxoguanine bases, and single-strand breaks 
are repaired through base excision repair (BER). The modified bases are flipped out of 
the duplex by a DNA glycosylase. The base is then excised from the DNA resulting in an 
abasic site. Incision of the DNA occurs at the abasic site, allowing for the 5’-baseless 
sugar to be removed and single base gap filling synthesis. The resulting nick is sealed 
completing the repair. 
Double strand breaks (DSBs) and interstand cross-links arising from X-ray 
irradiation and anti-tumor agents such as cis-platin and mitomycin C (MMC) are repaired 
by the two branches of recombinational repair, homologous recombination (HR) and non-
homologous end joining (NHEJ). HR is preferred and utilizes sister chromatids as 
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templates to precisely repair the genomic sequence, while NHEJ is an error-prone 
approach that links the two ends of a DSB together when HR is not possible.1,2  
 
Figure 2. DNA Damage repair pathways specialized in repairing specific types of damage. 
 
1.2 – DDR role in cancer progression 
Over time, errors occur during replication and unrepaired damage builds up, 
which can lead to mutations in the genetic code. These mutations can disrupt the 
regulation of gene expression, resulting in uncontrolled cell proliferation and cancer. In 
2005, two papers were published that brought forth a new model of how the DDR was 
involved in tumorigenesis in which DNA damage checkpoints become active in the early 
stages of tumorigenesis, providing a barrier to early tumor progression and directing cells 
to apoptosis. These studies reported evidence of an activated DDR response, noticeably 
phosphorylation of histone H2AX, ATM activation, RAD17 phosphorylation, CHK1 
phosphorylation, and localization of oncogene binding proteins, from precancerous and 
cancerous lesions and tumor tissue. The authors proposed a mechanism leading to 
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genomic instability in early development: aberrant stimulation of cell proliferation leads 
to replication stress, which can activate the DNA damage checkpoint(s). The activation of 
the checkpoint(s) induces cell cycle arrest or apoptosis, which functions as a tumor 
suppressor.22,23  
The following year two more studies were reported with evidence that the DDR 
was involved in cellular senescence. Oncogene-induced senescence was found to result 
from a robust DNA damage response (DDR) to replication stress and double strand 
breaks. The results, from cells and cancerous tissues, suggested that oncogene expression 
leads to an increase in DNA replication events, DDR activation, and genome activation. 
These findings led the authors to suggest a model in which oncogene expression leads to 
hyper-proliferation and DNA hyper-replication leading to an accumulation of DNA 
damage and sparking activation of S-phase specific DDR. The DDR proficient cells in 
turn undergo cellular senescence. Cells with an ineffective DDR undergo unrestrained 
proliferation fueled by oncogene expression. These reports suggest that senescence, 
which, like apoptosis, functions as a barrier to tumorigenesis.24,25  
 
1.3 – Replication Protein A (RPA) 
Replication Protein A (RPA) is a modular, heterotrimeric single-strand DNA 
(ssDNA) binding protein essential for replication, damage response and repair, which 
was first identified as an essential factor for replication of simian virus 40 DNA. RPA is 
composed of three conserved subunits: RPA70, RPA32, and RPA14. The RPA70 subunit 
is composed of four oligonucleotide/oligosaccharide binding fold (OB-fold) domains, 
termed 70N, 70A, 70B, and 70C. The DNA binding domains, 70A, 70B, and 70C are 
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connected by short 10 and 15 residue linkers, while the protein interaction module 70N is 
connected to 70A by a long (~70 residue) linker. The RPA32 subunit has three domains: 
the disordered 32N, an OB-fold domain 32D, and a winged-helix domain 32C. RPA32 
participates both in protein interactions and binding ssDNA as the 32C domain is the 
other primary protein interaction domain of RPA, while 32D is involved binding to 
ssDNA. RPA32N is the site of poly-phosphorylation at seven sites within the first 32 
residues, which occurs in response to cell cycle progression or DNA damaging agents. 
Phosphorylation of RPA70 has also been observed in vitro and in vivo. RPA70C, 
RPA32D, and RPA14 form the timerization core of the three RPA subunits. RPA binds 
DNA in a 5’ → 3’ direction with decreasing affinity from 70A to 32D.7,8  
 
 
Figure 3. Domain mapping of Replication Protein A. 70N, A, B, C and 32D are all OB fold domains, 32C 
is unstructured and the n-terminus of RPA32 is unstructured. 
 
DNA processing proteins like RPA are thought to utilize a common set of features 
to drive the progression of processing by “handing-off” of DNA: modular organization, 
multiple interaction sites, modest affinity, versatile structural modules, and a 
competition-based mechanism to promote hand-off. Most, if not all binding partners of 
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RPA interact through multiple contact points. Although each individual interaction is 
only of modest affinity, generally high micromolar, the total affinity of the interaction is 
approximately the product of the individual interactions due to the linkage effect. The use 
of multiple, modest affinity interactions helps drive the progression of DNA processing 
as proteins can be shuttled in and out in a sequential order based on their respective 
affinity. The OB-fold domains of RPA serve as a platform for interactions with both 
ssDNA and proteins. RPA70N contains an OB fold that does not bind to ssDNA but 
instead binds a number of proteins including ATRIP, RAD9, RAD17, MRE11, and 
p53.9,26 RPA70A and 70B are used primarily for binding to ssDNA, but interactions with 
SV40 T-antigen helicase, XPA and DNA polymerase alpha-primase have also been 
mapped to these domains.27 
 
Figure 4. Electrostatic mapping of surface residues of RPA70N. The OB fold contains a large amount of 
basic residues, referred to as the basic cleft. 
 
The structures of all of the globular domains of RPA and of the multi-domain 
constructs such as the trimer core have been determined by x-ray crystallography or 
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NMR, but the knowledge of the organization of the quaternary structure of RPA is 
scarce.28-33 Thus our understanding of the global architectural changes that RPA 
undergoes has been limited. Recently the structure of the DNA binding core, RPA70ABC 
and 32D, of RPA from Ustilago maydis bound to a 32-mer DNA substrate was 
determined by the Palvetich group using X-ray crystallography. This represented the first 
view of the quaternary structure of the full ssDNA binding core of RPA engaged on 
ssDNA. The authors propose a key role for the linker between domains 70B and 70C, 
which has a central role in a four-way interface between 70B, 70C, and the intervening 
ssDNA between these domains that are not engaged in the binding pockets. They suggest 
that the engagement of the BC linker would serve as the key step in transitioning between 
the three different ssDNA binding modes of RPA.34 However, no supporting evidence 
was provided in support of this proposal. Moreover, the crystal structure has an 
extraordinarily high degree of packing contacts and the solution-based study described 
below shows that this architecture represents an extreme that cannot be highly populated 
in solution.  
Our lab has completed an in-depth study of the architecture of RPA alone and as 
it engages ssDNA using a combination of small angle x-ray and neutron scattering 
(SAXS and SANS) with molecular dynamics simulations. The authors report that: 1) the 
apo protein is somewhat less extended than anticipated; 2) upon binding to a 10-mer 
ssDNA substrate, RPA shifts to a more compact arrangement with both 70A and 70B 
engaging the DNA. At this point the trimer core still retains some flexibility. Upon 
binding longer ssDNA, which engages 70C and 32D from the trimer core, RPA 
transitions to a slightly more compact form and the flexibility between RPA70AB and the 
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trimer core is further reduced. The Rg value for the 30-nt binding mode is only 2 Å 
smaller than the 10-nt binding, suggesting relatively small global architectural 
rearrangements when the 70C and 32D in the trimer core are engaged. These results 
contrast with the widely accepted model in which RPA has three modes of binding 
ssDNA: there is no evidence for a distinct intermediate DNA binding model.35 Overall, 
these studies presented new insights on the remodeling of RPA architecture and how this 
drives the progression of the DNA processing machinery. 
 
1.4 – Inhibiting the DDR  
The key development in understanding DDR was the discovery of its role in 
creating a barrier to tumorigenesis through apoptosis and senescence. This, along with 
additional research that has shown initial lesion generation by oncogenes is due to 
replication stress, has led to efforts to develop small molecule inhibitors (SMIs) of the 
DDR as a cancer therapeutic. Some success has already been seen with poly ADP-Ribose 
polymerase (PARP) inhibitors and their involvement in BRCA mutation-associated 
breast cancer.36,37 Many groups have also looked into inhibiting key members of the ATR 
signaling cascade, including ATR, RPA, and CHK1. 
ATR signaling inhibitors are expected to sensitize cells to DNA-damaging agents. 
Thus, cancer cells may be more dependent on replication stress responses than normal 
cells to complete replication and remain viable. Replication in the presence of DNA 
damage may lead to mitotic catastrophe, an event in which a cell is destroyed during 
mitosis because of aberrant chromosome segregation or DNA damage.9 Current cancer 
treatments involve chemo- and radio- based therapies that induce DNA damage, resulting 
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in signaling for repair and/or apoptosis. If this is combined with potential inhibitors of the 
DDR proteins such as CHK1 or ATR, this could prevent repair of the cancer cells, 
making them more toxic and ideally signaling them for apoptosis.38 
 
Inhibiting ATR 
In 1999, caffeine was identified to be an inhibitor of ATR and ATM.39 Caffeine 
had previously been known to sensitize cells. Although the concentrations that were 
determined to inhibit ATR are well above the acceptable concentration for therapeutic 
use, it serves as good inhibitor for biochemical studies of understanding ATR signaling 
and CHK1 activation. Recently a group has developed a high throughput cellular assay 
system to identify ATR inhibitors. Their system used a fusion of the ATR activation 
domain of TopBP1 with a fragment of the estrogen receptor, TopBP1ER to activate ATR. 
This screen captures molecule that inactive the ATR response. ATRi only inhibits CHK1 
phosphorylation, while DDRi was found to inhibit ATR as well as ATM, CHK2, and 
DNA-PKcs. DDRi is a previously identified compound as a dual PI3K and mTOR 
inhibitor with strong anticancer activity.40  
 
Inhibiting CHK1 
Development of small molecule inhibitors for CHK1 has been under investigation 
for over a decade. Biochemical studies showed that inhibition of CHK1 results in a rapid 
and strong phosphorylation of ATR targets in S-phase cells. This is accompanied with an 
increase in firing of DNA replication origins, massive induction of ssDNA, generation of 
double strand breaks, resulting in a destabilization of the genome. These observations 
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suggest that CHK1 mediates control of the initiation of DNA synthesis required for 
normal progression though S-phase in human cells. Additionally, it is thought that CHK1 
inhibition causes DNA breaks and activation of ATR due to lack of CHK1-mediated 
maintenance of stalled replication forks. CHK1 and ATR are both required to prevent the 
collapse of these stalled replication forks after treatment with replication inhibitors. ATR 
is required to prevent fork collapse during normal S-phase and avoid chromosomal break 
during mitosis. It is possible that CHK1 is required to prevent fork collapse during 
normal S-phase progression based on the results.38   
Several CHK1 inhibitors have been tested in pre-clinical and trials as potential 
cancer therapeutics. Early preclinical trials with UCN-01 were promising but phase 1 
clinical trials were unsuccessful as UCN-01 had a small volume of distribution, low 
systemic clearance, and a prolonged half-life, both due to its high binding affinity to α1-
acid glycoprotein (AAG) in human plasma.41-43 AZD772 is a urea-based inhibitor that is 
potent for CHK2 but is >10 fold more selective for CHK1, which was optimized from a 
high-throughput screening hit. It enhances the antitumor activity and abrogates S- and/or 
G2-phase checkpoints mediated by both antimetabolites and DNA-damaging agents. 
Results from phase 1 clinical trials have yet to be published.44-46 PF477736 is a 
diazepinoindolone-based inhibitor of CHK1 but also significantly inhibits CHK2, 
although this inhibitor is 100-fold more selective for CHK1. This inhibitor abrogates the 
induction of cell cycle checkpoints and potentiates the activity of several DNA-damaging 
agents across a broad spectrum of p53-deficient human cancer preclinical models. This 
inhibitor was discontinued as of September 2010.47-49 SCH900776 is an ATP-competitive 
inhibitor of CHK1. Unlike the previous two inhibitors it does not have affinity for CHK2; 
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however, it does have activity towards CDK2. This off-targeting effect on CDK2 could 
reduce the efficacy of this inhibitor as inhibition of CDK2 could induce cell cycle arrest 
and prevent checkpoint bypass in response to CHK1 inhibition. Phase 1 trials are ongoing 
with the goal of determining dosing for phase II trials.50,51  
 
Inhibiting RPA 
Inhibition of RPA has becoming an increasing popular target due to its many roles 
in DDR and repair. The N-terminal OB-fold domain of the RPA70 subunit (RPA70N) is 
known to interact with RAD9, RAD17, and ATRIP, all of which are involved in CHK1 
activation. Studies from the Turchi group have identified multiple small molecule 
inhibitors of RPA using an electromobility shift assay (EMSA). They found compounds 
that inhibit the RPA70AB OB fold domains, which are the initial, high affinity ssDNA 
binding domains, as well as two compounds that inhibit RPA but not via RPA70AB. 
Similar to caffeine inhibition of ATR, these inhibitors are very weak (high micromolar) 
binders that are not potent enough to be used as a therapeutic but have some potential for 
use in biological assays.52-54  
Other groups found small molecules that bind to the RPA70N domain, in the 
basic cleft that is the primary interaction surface with ATRIP and other DDR proteins. 
One group has identified a compound using an ELISA-like high throughput assay. The 
compound was selected based on its ability to inhibit the RAD9-RPA70N interaction, a 
known interaction during ATR signaling. Molecular modeling suggested that it mode of 
action was by binding to and competing for the RPA70N basic cleft though no direct 
evidence has been obtained. However, in agreement with the modeling, the compound 
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was also found to have no effect on the binding of ssDNA, suggesting it does not interact 
with any of the four domains involved (RPA70A, B, C and RPA32D), leaving RPA70N 
and RPA32C as prime targets.55 
Work from a collaboration the Chazin and Fesik laboratories has produced a high-
throughput fluorescence polarization assay to identify small molecules that bind to 
RPA70N. Compounds are selected based on their ability to displace a FITC-labeled 
ATRIP peptide from the basic cleft of RPA70N. This assay was tested using the 
compound identified by the ELISA-like technique and a similar binding affinity was 
obtained. Multiple small molecules have been identified using this fluorescence 
polarization assay of varying affinity.56 This thesis presents studies that are part of the 
effort to identify potent inhibitors of RPA70N protein interactions.  
 
1.5 – Methods to identify small molecule inhibitors of protein-protein interactions 
Fragment-based drug discovery (FBDD) has become an increasingly popular 
route to the development of potent small molecule inhibitors. The approach is based on 
the identification of multiple low mass, weakly binding fragments that are linked together 
to generate high overall affinity. FBDD is applicable to high throughput screening, which 
allows for large fragment libraries typically containing thousands of molecules to be 
screened in a rather short time frame. Constructing suitable libraries can be a difficult 
task as fragments for protein-protein interactions tend to be more hydrophobic and 
heavier than fragments for other applications such as targeting kinases. Since the each 
fragment could potentially be a scaffold for a future compound, it is important to avoid 
reactive, toxic, and unstable fragments containing alkylating or acylating groups, as these 
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can lead to unwanted products. Fragments libraries are typically used in medium or high-
throughput screening, which can involve a wide variety of different techniques.57 
  Fluorescence-based thermal shift (TS) detects compounds that increase the 
unfolding temperature of the target protein by binding to and stabilizing the folded state 
of the protein. This technique should be seen as an enrichment screening of the target 
library, as a hit is usually measured a ΔT = 1 oC, these results are not always highly 
reproducible.57,58 
Fluorescence anisotropy has been used frequently because it can be easily adapted 
to high throughput screening. A fluorophore is attached to a small molecule tumbling fast 
in solution. When the small molecule becomes bound to the target biomolecule the 
tumbling rate slows down dramatically and a difference in anisotropy can be measured. 
The major challenge in this approach is the need to label each fragment molecule with a 
fluorophore. It is much more common to use a displacement assay where a fluorescently 
labeled ligand is pre-bound to the protein and screening is made to find molecules that 
displace the probe.56 
 Nuclear Magnetic Resonance (NMR) Spectroscopy has been used extensively in 
identification of small molecules. A wide range of approaches have been developed. 
Typically in 1D experiments (STD, WaterLOGSY, TINS) protein or ligand signals are 
monitored, with attenuation of intensity indicating the presence of a binder.57,59-62 In 
strategies that use 2-dimensional (2D) NMR like SAR by NMR, target molecules are 
titrated with ligands and chemical shifts are monitored and perturbations of select shifts 
indicate the presence of a binder.63 If assignments are available, 2D experiments can give 
information on the location of the ligand.  
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X-ray crystallography provides validation of hits and structural binding 
information in one step. If crystallization conditions are known then a crystallographic 
approach can be robust; as synchrotron collection and molecular replacement allow for 
quick, high resolution structures. Direct screening of compounds has been utilized in 
certain applications where the libraries are limited and high through-put crystallography 
systems are available.57,64,65 
Surface plasma resonance (SPR) has also been used for screening. SPR requires 
the target protein to be covalently linked to gold clusters on the SPR biosensor chip and 
fragment solutions are passed over the chip. As fragments bind the change in mass is 
measured in real time. From the time dependent association-dissociation events, binding 
kinetics and affinities can be calculated.57,66,67  
Computation-based virtual screening is another widely used approach. It typically 
involves one of two strategies: (i) produce a structural model of the binding mode of a 
known hit fragment when no structural data is available; (ii) in silico screening. For 
docking of ligands to be useful for screening, it must not only produce the correct binding 
mode but must take in to account free energy change of the ligand in solvent binding to 
the protein.57,68,69  
In FBDD, after a hit or hits from a fragment are verified, generally the fragment is 
elaborated to produce analogs that bind tighter, have more drug-like properties, and help 
selectivity. Elaboration is usually achieved by one or a combination of different 
techniques. Merging is the incorporation of structural portions of overlapping molecules 
into a fragment, using structural information of other known fragments, substrates, and 
ligands in complex with the protein. Linking is the efficient “linking” of two fragments 
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that are known to bind in non-overlapping sites. A set of fragments that bind at a single 
site are discovered and “grown” through chemical synthesis to explore further 
interactions. Typically a common chemical scaffold is found and modifications are grown 
off of the scaffold.57 
A paper by Shuker et al, highlights many of the strategies discussed above and 
introduces the methodology for a technique designed to obtaining structure-activity 
relationships of small molecules with proteins using NMR. Selected small molecules can 
then be linked together using synthetic chemistry to obtain high-affinity ligands. This 
approach, commonly referred to as SAR by NMR (Structure-Activity Relationships by 
Nuclear Magnetic Resonance), allows the user to obtain the structure-activity 
relationship by monitoring chemical shift perturbations of 15N heteronuclear single 
quantum coherence spectra (HSQC). The process involves screening against a library for 
identification of a fragment molecule that binds to a specific site of the protein. This 
molecule is then optimized to obtain a higher affinity analog. The second fragment 
molecule is identified by performing the screens with saturating amounts of the first 
fragment molecule. This helps ensure that the second fragment binds in a different 
location than the first. Once a second site binder is identified, the molecule is optimized 
and then is attached to the first fragment molecule by building a carbon linker using 
synthetic chemistry. These linked fragments should yield a high-affinity compound as the 
binding affinity of the compound is the product of the two fragment molecules plus a 
term that accounts for changes in binding affinity due to linkage.63 The compounds 
investigated here were generated using the SAR by NMR approach. 
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Figure 5. Overview of Structure-activity relationships (SAR) by NMR. 
21 
 
Chapter 2 
 
Evaluation of the Accuracy of Autodock Vina for Modeling the Binding to RPA70N 
of Molecular Fragments from the Vanderbilt SAR-by-NMR Library 
 
2.1 – Introduction and background 
Previous work on the project to discover high affinity inhibitors of RPA70N 
protein interactions involved SAR by NMR screening of a curated 15,000-member 
fragment library. Two dimensional (2D) 15N-1H heteronuclear signal quantum coherence 
(HSQC) NMR spectroscopy was used to identify fragments that interact with the basic 
cleft of RPA70N. Fragments that were determined to interact by monitoring chemical 
shift perturbations, were then further classified based on whether their primary interaction 
site was S55 (site 1) or T60 (site 2). Identification of promising fragments were chosen as 
leads. These leads were optimized, leading to the production of analogs and the synthesis 
of potent compounds from these analogs. The binding affinities of the compounds were 
tested using a high throughput fluorescence anisotropy binding assay. Affinities were 
measured based on the ability of compounds to displace a FITC-labeled ATRIP peptide 
from the basic cleft of RPA70N.56 A select number of compounds of interest were chosen 
for crystallization.  
Initial crystallization attempts of wild-type (WT) RPA70N were successful in 
crystallizing the protein but the crystal packing was not ideal for co-crystallization with 
ligands as access to the basic cleft is blocked by an interaction with the C-terminus of a 
symmetry mate in the unit cell. This prompted Dr. Michael Feldkamp to re-engineer 
RPA70N by introducing charge reversal E-R point mutations at E7 and E100. Both single 
22 
 
mutations and the double mutant were prepared and all resulted in a change in crystal 
packing. Instead of the basic cleft being occluded, the mutations caused the protein to 
pack in a way that the basic cleft of symmetry mates forms an open channel. This channel 
allows for full access to the basic cleft for solvent and ligands. All of the structures 
discussed here were determined with the E7R mutant. For convenience, the E7R mutation 
will not be stated each time the structure of RPA70N is mentioned. 
In the present study, we were interested is the applicability of Autodock Vina as a 
virtual screening tool.70 In order to assess the applicability of this approach, six 
compounds were studied that were first selected from the original SAR by NMR screen 
and then elaborated. Four of the compounds have been co-crystallized with RPA70N and 
the other two have no structural data available. For the compounds that were not 
crystallized, two sets of runs were performed using different RPA70N structures. One 
was crystal structure of the protein alone (2B29) and the other is the RPA70N structure 
extracted from the co-crystal structure of the complex with an ATRIP peptide (2B3G).26 
By using a free and bound state of the protein, different binding sites may be revealed 
and information can be inferred about what residues are involved in binding of the ligand. 
 
2.2 – Experimental methods 
Molecular models were generated using Autodock Vina version 1.1.2. A series of 
comparisons were made for models generated for different exhaustiveness values. The 
exhaustiveness is a function that controls how “exhaustive” a search the program 
performs to find a global minimum. Default setting have an exhaustiveness value = 8. 
Other values tested in this study are 64, 128, 512, and 2048 for select compounds. 
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Exhaustiveness values between 8 and 64 represent values that would be ideal for 
screening, as they provide rapid results. Higher exhaustiveness values perform more 
extensive search but are inefficient time wise for screening. A test was also made to 
compare free docking to anywhere on the target molecule to guided docking in which a 
region of the target is specified as containing the binding surface. The results from these 
studies are presented below for each compound. 
To validate that all compounds bound as expected in the basic cleft of RPA70N, 
NMR chemical shift perturbations induced in the protein were measured for each of the 
six compounds. Samples of 15N-enriched RPA70N were prepared using standard 
methods. Solutions of the labeled protein at 130 M concentration were prepared in a 
buffer containing, 10 mM Tris pH 7.5, 250 mM NaCl, and 10% 2H2O. 
15N-1H SO-fast 
HSQC NMR spectra were acquired for each sample in the absence and presence of the 
compound, which was added as a 10 M solution in 13 L of DMSO. Using the 
assignments of the RPA70N of 15N and 1H backbone resonances, the location of the 
binding site was extracted based on the residues whose chemical shifts were perturbed by 
addition of the compound. The NMR spectral overlays are shown in Figure 6. 
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Figure 6. 
15
N-
1
H HSQC overlays of compounds used in this study with black as the free protein and red as 
the final titration point. (a-VU0467976, b-VU0468049, c-cVU0085636, d-VU0466242, e-VU0469701, f-
VU0100560) 
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2.3 – Results 
VU0467976 
Guided dock experiments resulted in placement of the phenyl furan 2-carboxylic 
acid portion of the compound in the correct orientation using the default settings 
(exhaustiveness = 8). Increasing the exhaustiveness to 64 generated a model that closely 
mimics the position in the crystal structure as seen in Figure 7. Further increasing the 
exhaustiveness resulted in similar models as seen previously.  The lowest energy model 
generated had an affinity = -10.6 kcal/mol.  
F 
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Allowing the program to search the entire molecule yielded results similar to what 
was seen when the search space was restricted to the basic cleft. Default settings were 
able to place the phenyl furan 2-carboxylic acid in the “correct” location. Increasing the 
exhaustiveness gave similar results as the program was able to orient the molecule in the 
same space as seen in the crystal structure, also shown in Figure 7. The lowest energy 
model had an affinity = -10.6 kcal/mol. This value is the same as what was seen for the 
guided model. Overlaying both generated lowest energy structures onto the crystal 
structure, good agreement of the placement and orientation of the compound is observed. 
NMR titrations show perturbations of residues in expected localized areas.  
 
 
 
Figure 7. Lowest energy models from guided (left, blue) and unguided (right, blue) overlaid on the crystal 
structure (red). 
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VU0468049   
For this compound, guided docking with default settings were sufficient to 
correctly orient the phenyl furan 2-carboxylic acid portion of the compound at site 2. 
Increasing the exhaustiveness to 128 generated a low energy model (affinity = -8.4 
kcal/mol) that recapitulated the crystal structure as seen in Figure 8. NMR titration 
experiments found a subset of chemical shift perturbations that have were mapped onto 
the surface of the protein. These perturbations are localized to the basic cleft where the 
compound was bound in the crystal structure. 
Unguided docking generated a model of equal predicted affinity as the guided 
model, but the site found was outside of the basic cleft. The compound was docked to a 
patch on the backside of RPA70N shown in Figure 8. The carboxylic acid off of the 
phenyl furan constituent is stabilized by positive charge from L104 and the amine groups 
are stabilized by negative charge from E98 and E100. No compounds were observed in 
the basic cleft in the unguided experiments even though model from the guided 
experiments had a predicted affinity equal or weaker than all complexes generated in the 
unguided experiments. 
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Figure 8. Lowest energy models from guided (left, blue) and unguided (right, blue) of VU0468049 
overlaid on the crystal structure (red). 
 
VU0085636   
For this compound, guided docking with default settings were sufficient to model 
the compound in the basic cleft but unable to align the model with the crystal structure. 
Increasing the exhaustiveness did not generate a lower energy model, all of the lowest 
energy models from each different exhaustiveness value had an affinity = -7.7 kcal/mol. 
Additionally none of these models correctly aligned with the structure showing; variation 
in the linkers between each of the phenyl rings was observed as shown in Figure 9. 
Unguided docking did not reproduce what was seen in the guided experiments. 
Unguided models favored a slightly basic and hydrophobic pocket formed on the back 
side of RPA involving the –SH of the GSH tag, resides 3-5 of the N-terminus, V76, 
L102, and K103. The lowest energy model (affinity = -8.7 kcal/mol) derived from 
unguided searches was positioned in this pocket on the backside of RPA and was 1 
kcal/mol lower than the guided model. This model is shown in Figure 9.  
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Figure 9. Lowest energy models from guided (left, blue) and unguided (right, blue) of VU0085636 
overlaid on the crystal structure (red). 
  
VU0466242  
For this compound, guided docking with default settings generated models with 
the compound at site 2. Increasing the exhaustiveness to 128 generated a model with 
similar orientation but the sulfur adopts a different conformation. A low energy model 
(affinity = -6.7 kcal/mol) with good agreement with the crystal structure was generated 
with an exhaustiveness = 2048, shown in Figure 10.  Values this high allow for much 
greater sampling of the space and lower energy models at the cost of time.   
Unguided experiments did not yield any models with the compound bound to the 
basic cleft (Figure 10). The majority of the unguided models were on the backside of the 
protein in small pockets. These pockets are composed of mainly hydrophobic residues 
with one or two charged residues to bind the carboxylic acid or amine groups of the 
compound. The lowest energy model (affinity = -6.5 kcal/mol) docked to the backside of 
S55 away from the basic cleft.  
34 
 
 
Figure 10. Lowest energy models of VU0466242 from guided (left, blue) and unguided (right, blue) 
experiments overlaid on the crystal structure (red). 
 
VU0469701 
This compound was docked to two different structures of RPA70N (PDB id: 
2B29 and 2B3G) because no structural data exists for the complex of this compound with 
RPA70N. Guided docking using the structure of RPA70N alone (2B29) identified a 
surface on the basic cleft that was favored for most models, including the lowest energy 
model (Figure 11). Residues I33, S38, P39, P40, R41, R43, and M57 form a basic and 
hydrophobic surface on loop 12(L12). Docking to this surface using the default 
parameters produced a low energy model and exhaustiveness did not further refine this 
model. 
Unguided docking produced a low energy model that binds in a hydrophobic and 
basic pocket behind the basic cleft. Residues T52, L53, S54, S55, R91, Y118, N119, and 
E120 form the pocket and are shown in Figure 11. The unguided model had an affinity = 
-6.0 kcal/mol compared to -5.0 kcal/mol for the guided model.  
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Figure 11. Lowest energy model of VU0469701 from guided (left) and unguided (right) experiments with 
pdb 2B29. 
 
 Guided docking using the structure of RPA70N from its complex with an ATRIP 
peptide (2B3G) provided a slightly lower energy model than with docking to the free 
RPA70N domain, -5.2 kcal/mol versus -5.0 kcal/mol, respectively. The compound was 
positioned in a small hydrophobic and basic pocket involving residues R43, S55, M57, 
L87, R91, and V93 (Figure 12). Use of the default settings did not identify the lowest 
energy model but as the exhaustiveness of the search was increased, the same location 
was targeted in all successive runs. Rearrangements in the orientation of the compound 
account for the changes seen in the affinity for each run.  
Unguided docking using structure 2B3G yielded models that were similar to the 
models produced with 2B29 (Figure 12). The compound was positioned in a basic and 
hydrophobic pocket formed by residues R43, L45, T52, L53, S54, S55, R91, and E120. 
Docking to 2B3G produced a model that was of higher energy than the 2B29 model, e.g. 
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when exhaustiveness is set to 512, values of -5.7 kcal/mol and -6kcal/mol, respectively, 
were produced. 
 
Figure 12. Lowest energy model of VU0469701 from guided (left) and unguided (right) experiments with 
pdb 2B3G. 
 
VU0100560 
This compound was also docked onto two different structures of RPA70N (PDB 
id: 2B29 and 2B3G) because no co-crystal structure of this complex with RPA70N has 
been determined. Guided docking using the structure of RPA70N alone (2B29) with 
Wednesday default settings place the compound on a hydrophobic and basic surface on 
L12. This surface is comprised of residues I33, T35, S38, R41, and R43 and is 
highlighted in cyan in Figure 13. Increasing the exhaustiveness did not yield a lower 
energy model as the affinity remained -5.5 kcal/mol.  
Unguided docking experiments did not generate any models with the compound 
bound to the basic cleft. Using default parameters, models with lower energy than the 
guided docking model were obtained. The lowest energy model had an affinity = -6.4 
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kcal/mol and was docked to a hydrophobic pocket comprised of residues L62, P64, L65, 
and L99 (Figure 13).  
 
Figure 13. Lowest energy model of VU0100560 from guided (left) and unguided (right) experiments with 
pdb 2B29. 
 
Guided docking experiments using the structure of RPA70N in complex with an 
ATRIP peptide (2B3G) yielded lower energy models than the docking experiments 
performed using the structure of free RPA70N, -6.2 kcal/mol versus -5.5 kcal/mol, 
respectively. With the default settings, the compound was positioned in a basic and 
hydrophobic pocket formed by residues R43, S55, M57, N85, L87, R91, and V93 (Figure 
14). Increasing the exhaustiveness function from 8 to 512 resulted in a slightly lower 
energy model, -5.9 kcal/mol versus -6.2 kcal/mol.  
Unguided docking experiments generated models with the compound positioned 
in a patch of hydrophobic residues including I30, V66, E69, L71, S72, and S73 (Figure 
14). This model had an affinity = -6.5 kcal/mol. Additionally, two models were generated 
with the compound docked to the basic pocket as seen in the guided search, but these had 
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higher energies than the best model with the ligand positioned outside the RPA70N basic 
cleft.   
 
Figure 14. Lowest energy model of VU0100560 from guided (left) and unguided (right) experiments with pdb 2B3G. 
 
 
2.4 – Summary of findings 
 
Guided docking experiments were successful in recapitulating the position and 
orientation for the compounds that have previously been crystallized. All compounds 
with crystal structures of their complex with RPA70N overlay nicely with the position 
observed in the crystal structure except for VU0085636. The lowest energy model of 
VU0085636 provided the correct relative positions of the phenyl rings but did not match 
the orientation seen in the crystal structure. A general trend in the results was that the 
accuracy of the prediction correlated with the affinity of the compounds.  Moreover, the 
compounds with highest affinity (lower Kd values) required less exhaustive searches to 
recreate the structure observed in the crystal structure. VU0467976 was the tightest 
binder tested with a Kd of 8 µM. It also had the lowest energy model from all the 
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compounds tested, -10.6 kcal/mol. VU0468049 was the next tightest binder and produced 
the second lowest energy model, -8.4 kcal/mol. These two compounds were both 
successful in generating models that mimic the respective crystal structures in less 
exhaustive searches (64 and 128 respectively). VU0466242 a smaller compound and 
weaker binder (KD=164 µM) produced a higher energy “best” model, -6.7 kcal/mol and 
required a more exhaustive search (2048) to obtain that model. This correlation between 
the affinity of the compound and relative values of the energies reported is interesting, 
and presumably arises because the structure of the protein does not vary and the energy is 
dominated by the number of stabilizing contacts made by the compound. 
 Unguided docking experiments allowed for the entire surface of the protein to be 
sampled as opposed to be optimized to only sample the basic cleft of RPA70N, which 
serves as the binding site for target proteins. However, these unguided experiments were 
largely unsuccessful in regenerating the position of the compound in the crystal structure. 
In many cases, the pockets in which the compound was positioned was away from the 
basic cleft, i.e. lower energy models were generated with the compound docked outside 
versus in the basic cleft. Additionally, these experiments take a substantially longer time 
to run, as expected, since a higher exhaustiveness value is needed to adequately sample 
all of the space. The problem is made even more challenging when a smaller compound 
or fragment is investigated, as its small size allows for more binding sites to be sampled. 
Given the higher computational cost and uncertainty in the result, spending larger 
amounts of time modeling does seem to be advantageous. This is particularly true in the 
light of the availability of very rapid screening methods. The development of NMR pulse 
sequences allowing for collection of complete HSQC spectra in 15 minutes for well-
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behaved proteins at reasonably low concentrations is especially valuable in this context 
because it would allow at least a direct albeit coarse mapping of the ligand binding site. 
Overall, unguided docking does not appear to currently lend itself to be a valuable 
approach for screening. 
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Chapter 3 
 
Conclusion and Future Directions 
 
3.1 – Evaluation of overall performance of Autodock Vina  
This study evaluated the ability of Autodock Vina to serve as a tool in the 
development of small molecule inhibitors of RPA70N. Given the lack of success in 
recapitulating the crystal structure and the need for long, exhaustive unguided searches to 
adequately sample the space proved to be inefficient and unable to adequately predict the 
correct binding site. On the other hand, with some knowledge of the binding site on the 
target, the program did a remarkably good job at predicting the binding site. Additionally, 
we found a correlation between the accuracy of the prediction and the size of the 
compound: larger compounds like VU0467976 worked better. We attribute this 
observation to the fact that as the molecule gets larger the number of potential binding 
sites is reduced compared to small fragments like VU0466242. An inverse correlation 
between exhaustiveness and the Kd was observed for the tight binders in this group. 
These compounds required less exhaustive searches and produced lower energy models. 
Overall, my results suggest that Autodock Vina is not an efficient tool for 
screening large libraries of fragments but has the potential to be useful for rational drug 
design. Analogs of lead compounds can quickly be designed and prepared for docking as 
compared to synthesizing all of the compounds. Importantly, large number of analogs can 
be designed and efficiently modeled in one day. Given the correlations seen in this study, 
relative binding affinity between the compound and protein can be assessed from the 
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calculated energies. In particular, the lower the energy is, the tighter the binding. This 
will allow for the synthesis and testing of only those compounds that are highly likely to 
bind more tightly to the target. Should Autodock Vina program prove generally 
applicable, it would enhance the overall efficiency of the compound optimization 
process.  
 
3.2 – Future directions  
In efforts to continue evaluating the role of virtual screening and molecular 
docking in drug discovery, additional steps could be implemented for further evaluation 
of Autodock Vina. All of the experiments that were performed in this study kept the 
protein as a rigid body and only allowed certain bonds in the compounds to rotate in the 
docking. Autodock Vina allows for residues to set as flexible. Allowing residues in the 
basic cleft to retain flexibility should allow for better models. RPA70N was identified as 
having two discrete ligand binding sites in the basic cleft, centered on S55 and T60. 
Additionally, the side chains of residues R41, R43, and M57 were consistently identified 
as key contributors to the binding of the six compounds tested here. Allowing flexibility 
of these key residues alone may be a good compromise to obtain additional information 
about the targeted binding site without having as high of a computational cost as allowing 
flexibility to all side chains.  
If structural information is available on the target binding site, it would be worth 
evaluating the use of the program as a virtual screening tool. Fragments would be 
screened in a defined target area and could be separated based on their binding location. 
By performing this virtual screening, a chemist could see orientations and positions for 
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each fragment at a targeted binding site. Distances can be measured and the chemist can 
rationally design a linker to connect the fragments based on the set of models generated 
by the program. This approach would be beneficial in situations where complexes do not 
readily crystallize and no additional structural data is available.  
Additional testing should be performed to see if the correlation between tighter 
binding of the protein-ligand complexes and lower energies in Autodock Vina models. 
This study examined compounds with affinities between 8 µM and 170 µM. If this trend 
was to continue in to the nanomolar range, this approach would be an ideal method to 
predict which compounds and future analogs are worth pursuing synthetically. Ideally, 
this particular step would come later in the process, well after screening. However, as we 
have noted above, the use of computational evaluation of binding of ligands to a target 
protein can be useful at multiple stages of the compound optimization process. With the 
continual development of Autodock Vina and many other computational approaches, the 
future of drug discovery will very likely see an increase in overall efficiency as a result of 
these developments. 
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Appendix A 
 
Compounds used in study 
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Appendix B 
 
Energy values for all models 
 
 
VU0467976 Guided Ex = 8 VU0467976 Unguided Ex = 8 
Model Position Affinity (kcal/mol) Model Position Affinity (kcal/mol) 
1 -9.1 1 -8.1 
2 -8.9 2 -7.8 
3 -8.5 3 -7.5 
4 -8.4 4 -7.4 
5 -8.3 5 -7.4 
6 -8.2 6 -7.3 
7 -8.1 7 -7.3 
8 -8.0 8 -7.3 
9 -7.9 9 -7.2 
  
  
VU0467976 Guided Ex = 64 VU0467976 Unguided Ex = 64 
Model Position Affinity (kcal/mol) Model Position Affinity (kcal/mol) 
1 -10.6 1 -10.4 
2 -9.3 2 -9.8 
3 -9.3 3 -9.3 
4 -9.3 4 -9.2 
5 -9.3 5 -9.1 
6 -9.0 6 -9.1 
7 -9.0 7 -9.1 
8 -8.8 8 -8.7 
9 -8.8 9 -8.7 
  
  
VU0467976 Guided Ex = 128 VU0467976 Unguided Ex = 128 
Model Position Affinity (kcal/mol) Model Position Affinity (kcal/mol) 
1 -10.4 1 -10.6 
2 -9.4 2 -9.7 
3 -9.2 3 -9.4 
4 -9.2 4 -9.1 
5 -9.1 5 -9.1 
6 -9.1 6 -8.7 
7 -9.0 7 -8.6 
8 -8.8 8 -8.6 
9 -8.7 9 -8.5 
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VU0468049 Guided Ex = 8 
 
VU0468049 Unguided Ex = 8 
Model Position Affinity (kcal/mol) 
 
Model Position Affinity (kcal/mol) 
1 -7.5 
 
1 -6.8 
2 -7.3 
 
2 -6.7 
3 -7.2 
 
3 -6.5 
4 -7.1 
 
4 -6.5 
5 -7.0 
 
5 -6.5 
6 -7.0 
 
6 -6.4 
7 -6.8 
 
7 -6.4 
8 -6.6 
 
8 -6.2 
9 -6.5 
 
9 -6.0 
     VU0468049 Guided Ex = 64 
 
VU0468049 Unguided Ex = 64 
Model Position Affinity (kcal/mol) 
 
Model Position Affinity (kcal/mol) 
1 -7.9 
 
1 -8.4 
2 -7.8 
 
2 -8.3 
3 -7.8 
 
3 -8.2 
4 -7.8 
 
4 -8.1 
5 -7.7 
 
5 -8.1 
6 -7.7 
 
6 -8.1 
7 -7.6 
 
7 -7.9 
8 -7.4 
 
8 -7.8 
9 -7.4 
 
9 -7.8 
     VU0468049 Guided Ex = 128 
 
VU0468049 Unguided Ex = 128 
Model Position Affinity (kcal/mol) 
 
Model Position Affinity (kcal/mol) 
1 -8.4 
 
1 -8.3 
2 -8.1 
 
2 -8.2 
3 -8.0 
 
3 -8.2 
4 -8.0 
 
4 -8.2 
5 -8.0 
 
5 -8.1 
6 -7.9 
 
6 -8.0 
7 -7.8 
 
7 -8.0 
8 -7.8 
 
8 -7.9 
9 -7.8 
 
9 -7.9 
VU0085636 Guided Ex = 8 
 
VU0085636 Unguided Ex = 8 
Model Position Affinity (kcal/mol) 
 
Model Position Affinity (kcal/mol) 
1 -7.7 
 
1 -8.4 
2 -7.6 
 
2 -8.3 
3 -7.6 
 
3 -8.3 
4 -7.3 
 
4 -8.1 
5 -7.3 
 
5 -8.1 
6 -7.3 
 
6 -8.0 
7 -7.1 
 
7 -8.0 
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8 -7.1 
 
8 -8.0 
9 -7.0 
 
9 -8.0 
     VU0085636 Guided Ex = 64 
 
VU0085636 Unguided Ex = 64 
Model Position Affinity (kcal/mol) 
 
Model Position Affinity (kcal/mol) 
1 -7.6 
 
1 -8.7 
2 -7.6 
 
2 -8.4 
3 -7.5 
 
3 -8.4 
4 -7.5 
 
4 -8.3 
5 -7.3 
 
5 -8.3 
6 -7.3 
 
6 -8.3 
7 -7.3 
 
7 -8.2 
8 -7.2 
 
8 -8.2 
9 -7.2 
 
9 -8.2 
     VU0085636 Guided Ex = 128 
 
VU0085636 Unguided Ex = 128 
Model Position Affinity (kcal/mol) 
 
Model Position Affinity (kcal/mol) 
1 -7.6 
 
1 -8.7 
2 -7.6 
 
2 -8.5 
3 -7.5 
 
3 -8.4 
4 -7.5 
 
4 -8.4 
5 -7.4 
 
5 -8.3 
6 -7.3 
 
6 -8.3 
7 -7.3 
 
7 -8.2 
8 -7.3 
 
8 -8.2 
9 -7.3 
 
9 -8.2 
     VU0085636 Guided Ex = 512 
 
VU0085636 Unguided Ex = 512 
Model Position Affinity (kcal/mol) 
 
Model Position Affinity (kcal/mol) 
1 -7.7 
 
1 -8.7 
2 -7.6 
 
2 -8.5 
3 -7.5 
 
3 -8.5 
4 -7.5 
 
4 -8.4 
5 -7.4 
 
5 -8.3 
6 -7.3 
 
6 -8.3 
7 -7.3 
 
7 -8.2 
8 -7.3 
 
8 -8.2 
9 -7.3 
 
9 -8.2 
 
VU0466242 Guided Ex = 8 
 
VU0466242 Unguided Ex = 8 
Model Position Affinity (kcal/mol) 
 
Model Position Affinity (kcal/mol) 
1 -5.4 
 
1 -5.6 
2 -5.2 
 
2 -5.5 
3 -5.2 
 
3 -5.4 
4 -5.2 
 
4 -5.3 
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5 -5.0 
 
5 -5.3 
6 -4.9 
 
6 -5.3 
7 -4.8 
 
7 -5.1 
8 -4.8 
 
8 -5.1 
9 -4.7 
 
9 -5.1 
     VU0466242 Guided Ex = 64 
 
VU0466242 Unguided Ex = 64 
Model Position Affinity (kcal/mol) 
 
Model Position Affinity (kcal/mol) 
1 -5.8 
 
1 -6.2 
2 -5.8 
 
2 -5.9 
3 -5.7 
 
3 -5.8 
4 -5.7 
 
4 -5.7 
5 -5.6 
 
5 -5.7 
6 -5.6 
 
6 -5.7 
7 -5.6 
 
7 -5.7 
8 -5.5 
 
8 -5.7 
9 -5.4 
 
9 -5.7 
     VU0466242 Guided Ex = 128 
 
VU0466242 Unguided Ex = 128 
Model Position Affinity (kcal/mol) 
 
Model Position Affinity (kcal/mol) 
1 -6.2 
 
1 -6.2 
2 -6.1 
 
2 -5.6 
3 -6.0 
 
3 -5.6 
4 -5.9 
 
4 -5.6 
5 -5.7 
 
5 -5.5 
6 -5.7 
 
6 -5.5 
7 -5.7 
 
7 -5.5 
8 -5.7 
 
8 -5.5 
9 -5.7 
 
9 -5.5 
     VU0466242 Guided Ex = 512 
 
VU0466242 Unguided Ex = 512 
Model Position 
  
Model Position Affinity (kcal/mol) 
1 -5.8 
 
1 -6.5 
2 -5.8 
 
2 -6.4 
3 -5.7 
 
3 -6.0 
4 -5.7 
 
4 -6.0 
5 -5.7 
 
5 -5.9 
6 -5.6 
 
6 -5.9 
7 -5.6 
 
7 -5.9 
8 -5.6 
 
8 -5.8 
9 -5.5 
 
9 -5.8 
     VU0466242 Guided Ex = 2048 
 
VU0466242 Unguided Ex = 2048 
Model Position Affinity (kcal/mol) 
 
Model Position Affinity (kcal/mol) 
1 -6.7 
 
1 -6.6 
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2 -6.4 
 
2 -6.5 
3 -6.3 
 
3 -6.4 
4 -6.2 
 
4 -6.3 
5 -6.2 
 
5 -6.3 
6 -6.1 
 
6 -6.1 
7 -6.1 
 
7 -6.1 
8 -6.1 
 
8 -6.1 
9 -6.1 
 
9 -6.0 
 
VU0469701 - 2B29 Guided Ex = 8 
 
VU0469701 - 2B29 Unguided Ex = 8 
Model Position Affinity (kcal/mol) 
 
Model Position Affinity kcal/mol) 
1 -4.9 
 
1 -6.0 
2 -4.7 
 
2 -5.6 
3 -4.6 
 
3 -5.4 
4 -4.6 
 
4 -5.4 
5 -4.5 
 
5 -5.1 
6 -4.5 
 
6 -5.1 
7 -4.5 
 
7 -5.0 
8 -4.5 
 
8 -4.9 
9 -4.3 
 
9 -4.9 
     VU0469701 - 2B29 Guided Ex = 64 
 
VU0469701 - 2B29 Unguided Ex = 64 
Model Position Affinity (kcal/mol) 
 
Model Position Affinity (kcal/mol) 
1 -5.0 
 
1 -6.0 
2 -4.8 
 
2 -5.8 
3 -4.7 
 
3 -5.5 
4 -4.7 
 
4 -5.4 
5 -4.6 
 
5 -5.3 
6 -4.6 
 
6 -5.2 
7 -4.6 
 
7 -5.2 
8 -4.5 
 
8 -5.1 
9 -4.5 
 
9 -5.1 
     VU0469701 - 2B29 Guided Ex = 128 
 
VU0469701 - 2B29 Unguided Ex = 128 
Model Position Affinity (kcal/mol) 
 
Model Position Affinity (kcal/mol) 
1 -5.0 
 
1 -6.0 
2 -4.8 
 
2 -5.8 
3 -4.7 
 
3 -5.6 
4 -4.7 
 
4 -5.5 
5 -4.7 
 
5 -5.4 
6 -4.6 
 
6 -5.4 
7 -4.6 
 
7 -5.4 
8 -4.6 
 
8 -5.3 
9 -4.6 
 
9 -5.2 
     
50 
 
VU0469701 - 2B29 Guided Ex = 512 
 
VU0469701 - 2B29 Unguided Ex = 512 
Model Position Affinity (kcal/mol) 
 
Model Position Affinity (kcal/mol) 
1 -5.0 
 
1 -6.0 
2 -4.8 
 
2 -5.7 
3 -4.8 
 
3 -5.5 
4 -4.7 
 
4 -5.5 
5 -4.7 
 
5 -5.5 
6 -4.7 
 
6 -5.4 
7 -4.7 
 
7 -5.3 
8 -4.6 
 
8 -5.2 
9 -4.6 
 
9 -5.2 
     
VU0469701 - 2B3G Guided Ex = 8  VU0469701 - 2B3G Unguided Ex = 8 
Model Position Affinity (kcal/mol)  Model Position Affinity (kcal/mol) 
1 -5.2  1 -5.4 
2 -4.7  2 -5.4 
3 -4.5  3 -5.4 
4 -4.5  4 -5.3 
5 -4.5  5 -5.1 
6 -4.4  6 -4.9 
7 -4.4  7 -4.9 
8 -4.2  8 -4.8 
9 -4.1  9 -4.8 
     
VU0469701 - 2B3G Guided Ex = 64  VU0469701 - 2B3G Unguided Ex = 64 
Model Position Affinity (kcal/mol)  Model Position Affinity (kcal/mol) 
1 -5.2  1 -5.7 
2 -4.9  2 -5.6 
3 -4.8  3 -5.6 
4 -4.6  4 -5.6 
5 -4.6  5 -5.5 
6 -4.6  6 -5.4 
7 -4.6  7 -5.4 
8 -4.6  8 -5.4 
9 -4.5  9 -5.3 
     
VU0469701 - 2B3G Guided Ex = 128  VU0469701 - 2B3G Unguided Ex = 128 
Model Position Affinity (kcal/mol)  Model Position Affinity (kcal/mol) 
1 -5.3  1 -5.7 
2 -4.7  2 -5.7 
3 -4.7  3 -5.6 
4 -4.6  4 -5.6 
5 -4.6  5 -5.6 
6 -4.6  6 -5.5 
7 -4.6  7 -5.5 
51 
 
8 -4.5  8 -5.4 
9 -4.5  9 -5.4 
     
VU0469701 - 2B3G Guided Ex = 512  VU0469701 - 2B3G Unguided Ex = 512 
Model Position Affinity (kcal/mol)  Model Position Affinity (kcal/mol) 
1 -5.2  1 -5.7 
2 -4.9  2 -5.7 
3 -4.8  3 -5.6 
4 -4.7  4 -5.6 
5 -4.6  5 -5.6 
6 -4.6  6 -5.5 
7 -4.6  7 -5.5 
8 -4.6  8 -5.5 
9 -4.6  9 -5.5 
 
VU0100560 - 2B29 Guided Ex = 8 
 
VU0100560 - 2B29 Unguided Ex = 8 
Model Position Affinity (kcal/mol) 
 
Model Position Affinity (kcal/mol) 
1 -5.5 
 
1 -6.4 
2 -5.4 
 
2 -6.2 
3 -5.3 
 
3 -6.0 
4 -5.1 
 
4 -6.0 
5 -5.1 
 
5 -6.0 
6 -5 
 
6 -5.9 
7 -5 
 
7 -5.9 
8 -4.8 
 
8 -5.9 
9 -4.8 
 
9 -5.8 
     VU0100560 - 2B29 Guided Ex = 64 
 
VU0100560 - 2B29 Unguided Ex = 64 
Model Position Affinity (kcal/mol) 
 
Model Position Affinity (kcal/mol) 
1 -5.5 
 
1 -6.4 
2 -5.4 
 
2 -6.2 
3 -5.3 
 
3 -6.0 
4 -5.3 
 
4 -6.0 
5 -5.2 
 
5 -6.0 
6 -5.1 
 
6 -6.0 
7 -5.1 
 
7 -6.0 
8 -5.1 
 
8 -5.9 
9 -5 
 
9 -5.9 
     VU0100560 - 2B29 Guided Ex = 128 
 
VU0100560 - 2B29 Unguided Ex = 128 
Model Position Affinity (kcal/mol) 
 
Model Position Affinity (kcal/mol) 
1 -5.5 
 
1 -6.4 
2 -5.4 
 
2 -6.2 
3 -5.3 
 
3 -6.1 
4 -5.3 
 
4 -6.1 
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5 -5.2 
 
5 -6.0 
6 -5.1 
 
6 -6.0 
7 -5.1 
 
7 -6.0 
8 -5.1 
 
8 -5.9 
9 -5 
 
9 -5.9 
     VU0100560 - 2B29 Guided Ex = 512 
 
VU0100560 - 2B29 Unguided Ex = 512 
Model Position Affinity (kcal/mol) 
 
Model Position Affinity (kcal/mol) 
1 -5.5 
 
1 -6.4 
2 -5.4 
 
2 -6.2 
3 -5.3 
 
3 -6.1 
4 -5.3 
 
4 -6.1 
5 -5.2 
 
5 -6.0 
6 -5.1 
 
6 -6.0 
7 -5.1 
 
7 -6.0 
8 -5.1 
 
8 -5.9 
9 -5.1 
 
9 -5.9 
VU0100560 - 2B3G Guided Ex = 8 
 
VU0100560 - 2B3G Unguided Ex = 8 
Model Position Affinity (kcal/mol) 
 
Model Position Affinity (kcal/mol) 
1 -5.9 
 
1 -6.5 
2 -5.9 
 
2 -6.2 
3 -5.7 
 
3 -6.2 
4 -5.6 
 
4 -6.2 
5 -5.5 
 
5 -6.2 
6 -5.3 
 
6 -6.0 
7 -5.2 
 
7 -5.8 
8 -5.1 
 
8 -5.7 
9 -5.1 
 
9 -5.7 
     VU0100560 - 2B3G Guided Ex = 64 
 
VU0100560 - 2B3G Unguided Ex = 64 
Model Position Affinity (kcal/mol) 
 
Model Position Affinity (kcal/mol) 
1 -5.9 
 
1 -6.5 
2 -5.9 
 
2 -6.2 
3 -5.8 
 
3 -6.2 
4 -5.6 
 
4 -6.2 
5 -5.6 
 
5 -6.2 
6 -5.6 
 
6 -6.0 
7 -5.5 
 
7 -6.0 
8 -5.5 
 
8 -6.0 
9 -5.4 
 
9 -5.9 
     VU0100560 - 2B3G Guided Ex = 128 
 
VU0100560 - 2B3G Unguided Ex = 128 
Model Position Affinity (kcal/mol) 
 
Model Position Affinity (kcal/mol) 
1 -6.2 
 
1 -6.5 
2 -6.1 
 
2 -6.3 
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3 -6.1 
 
3 -6.2 
4 -5.8 
 
4 -6.2 
5 -5.8 
 
5 -6.2 
6 -5.8 
 
6 -6.0 
7 -5.7 
 
7 -6.0 
8 -5.7 
 
8 -6.0 
9 -5.5 
 
9 -5.9 
     VU0100560 - 2B3G Guided Ex = 512 
 
VU0100560 - 2B3G Unguided Ex = 512 
Model Position Affinity (kcal/mol) 
 
Model Position Affinity (kcal/mol) 
1 -6.2 
 
1 -6.5 
2 -6.1 
 
2 -6.2 
3 -6.1 
 
3 -6.2 
4 -5.8 
 
4 -6.2 
5 -5.8 
 
5 -6.2 
6 -5.8 
 
6 -6.0 
7 -5.8 
 
7 -6.0 
8 -5.7 
 
8 -6.0 
9 -5.7 
 
9 -6.0 
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